HIGHLIGHTS
- who: Yongbiao Chen and colleagues from the Third Military Univeristy, China, China, Fuzong Clinical College, Fujian University, China have published the research work: Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study, in the Journal: (JOURNAL)
- what: The study was approved by China Ethics Committee of Registering Clinical Trials (Ethical review document number: ChiECRCT20200128) and informed consent was obtained from all patients, whose data will be used for research purposes, according to the Declaration of Helsinki. In the cohort , all patients in the study showed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.